NASDAQ:OKYO OKYO Pharma Q2 2026 Earnings Report $1.36 +0.04 (+3.03%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.38 +0.01 (+1.10%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast OKYO Pharma EPS ResultsActual EPS-$2.28Consensus EPS -$0.07Beat/MissMissed by -$2.21One Year Ago EPSN/AOKYO Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOKYO Pharma Announcement DetailsQuarterQ2 2026Date1/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsOKYO Pharma's Q1 2027 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedulesConference Call ResourcesEarnings HistoryCompany Profile OKYO Pharma Earnings HeadlinesOKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026September 9, 2026 | globenewswire.comOKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare ConferenceSeptember 8, 2026 | globenewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)OKYO Pharma Announces Purchase of Shares by Chief Scientific OfficerJuly 28, 2026 | globenewswire.comOKYO Pharma to Participate in the BTIG Biotechnology Conference 2026July 27, 2026 | globenewswire.comOKYO Pharma Announces Purchase of Shares by DirectorJuly 23, 2026 | globenewswire.comSee More OKYO Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OKYO Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OKYO Pharma and other key companies, straight to your email. Email Address About OKYO PharmaOKYO Pharma (NASDAQ:OKYO) Limited is a clinical-stage biotechnology company focused on discovering and developing precision medicines that target G protein-coupled receptors (GPCRs). The company’s research is directed toward treatments for inflammatory, autoimmune and pain-related conditions, including diseases affecting the eye. OKYO’s lead development program is OK-101, an investigational GPCR-targeted therapy being studied for ocular conditions such as dry eye disease. The company has also explored potential applications of its platform in neuropathic pain and other diseases involving inflammation and immune-system signaling. Its drug candidates remain investigational and are subject to clinical and regulatory evaluation. OKYO Pharma is based in the United Kingdom and conducts development activities aimed at serving international pharmaceutical and healthcare markets. The company’s shares trade on the Nasdaq Capital Market under the symbol OKYO.View OKYO Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
